Study: Marinol Reduces Agitation, Improves Appetite in Alzheimer Patients

The drug Marinol® (dronabinol) reduces agitation and improves appetite in Alzheimer's disease patients, according to data presented August 20 at the International Psychogeriatric Association meeting in Chicago.

Marinol is the synthetic version of the active ingredient in marijuana. Lead researcher Dr. Joshua Shua-Haim, medical director of the Meridian Institute for Aging in New Jersey, said the drug also appears to be safe for Alzheimer's patients.

Marinol is the only drug of its kind approved by the U.S. Food and Drug Administration and is currently indicated for the treatment of anorexia in patients with HIV/AIDS and for nausea and vomiting associated with cancer chemotherapy.

Agitation is the most frequently encountered type of behavioral disturbance associated with Alzheimer's disease. Weight loss is also a common problem of the disease as Alzheimer's patients are unable to recognize hunger and thirst.

"It's important to look at all the aspects of Alzheimer's disease that contribute to quality of life for patients, family members and caregivers," said Shua-Haim. "Agitation and weight loss are upsetting and stressful as the patient's needs become ever more demanding."

The study involved 48 Alzheimer's patients who were anorexic and often agitated. All of the patients received daily doses of dronabinol. Thirty-one patients experienced a significant improvement in agitation and all patients gained weight. No adverse events, such as falls, loss of consciousness, seizures or exacerbation of agitation or depression, were reported as a result of treatment.

Other sources: Meridian Health System